Balaji Amines Ltd Q1 FY22 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- After completion of all expansions (acetonitrile, DMC, ethylamine), Balaji Amines expects total volumes to be around 120,000 to 130,000 tonnes per annum, excluding the 50,000 tonnes greenfield methylamine capacity.
- Current specialty product volumes are approximately 20,000 to 25,000 tonnes annually; full expansion could increase this significantly.
- Revenue guidance for the company is around Rs. 1,800 to 2,000 Crores in two years, with potential to exceed Rs. 2,000 Crores if new DMF plant also materializes.
- The ethylamine plant, recently commissioned, has reached over 90% capacity utilization and will continue to drive revenue growth (Rs. 200-300 Crores annually at full capacity).
- The upcoming DMC plant is expected to start by the end of FY2022, targeting approx. Rs. 150 Crores in annual revenue.
- Acetonitrile plant expansion (50 TPD) planned to commence operations in FY2023 with CapEx of Rs. 70-80 Crores.
- Higher capacity utilization and improved price realizations are expected to enhance profitability alongside volume growth.
See what Balaji Amines Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
- The transcript on page 17 and surrounding pages does not mention any current or future plans for fundraising through debt or equity.
- The focus is primarily on capacity expansions and capital expenditure funded through internal accruals or operational cash flows.
- CapEx plans discussed include Rs. 70-80 Crores for acetonitrile plant in FY2023 and additional investments in methylamine and DMC plants.
- There is no explicit mention of raising funds via new debt or equity issuances in the discussed calls.
- The company appears focused on operational efficiency and phased expansions rather than fresh fundraising drives.
See what Balaji Amines Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- Balaji Amines has planned multiple expansions including acetonitrile, dimethyl carbonate (DMC), methylamines, and DMF plants.
- CapEx of Rs. 70 to 80 Crores is planned for a new acetonitrile plant (50 TPD) expected to commence operations in FY2023.
- A new DMC plant is under construction aiming to start production by end of FY2022.
- Additional investments of Rs. 53 Crores are expected to complete the phase 1 Greenfield Project, with a total of Rs. 172 Crores already spent till June 30, 2021.
- CapEx for FY2022 is estimated around Rs. 50 to 60 Crores, including the final part of the ethylamine plant and DMC plant.
- New methylamine plant capex is expected to begin in FY2023, with exact costs to be clarified later.
- A new co-generation power plant (4.9 MW) is planned to be operational within a few months to reduce costs.
- No major backward integration beyond oxygen and power plants is planned due to scale and complexity.
Track Balaji Amines Ltd — get its next earnings analysis in your feed
Margin guidance
Category 3- Capacity utilization is increasing from 20-30% earlier to 40% now, expected to reach 60-70%, leading to further profitability improvement.
- Sustainable EBITDA margin expected at 20-23% long-term; currently achieving 28-30% due to short supply and strong demand.
- Revenues projected to rise above Rs. 1,800 to Rs. 2,000 Crores in 2 years post expansions, potentially Rs. 2,000-2,500 Crores with new DMF plant.
- New ethylamine and DMC plants expected to generate Rs. 200-300 Crores and Rs. 150 Crores of revenue annually at full utilization.
- EPS grew significantly from Rs. 10.17 (Q1 FY2021) to Rs. 27.90 (Q1 FY2022), indicating growth momentum.
- Expansion in product volumes targeting 120,000-130,000 tonnes combined (excluding methylamine greenfield capacity).
- Increased capacity and new technology adoption expected to lower costs and improve margins further.
Order book
How does Balaji Amines Ltd rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Balaji Amines Ltd rank in Chemicals & Petrochemicals?
Compare Balaji Amines Ltd against every Chemicals & Petrochemicals company (Q1 FY22) on revenue, margins and earnings-call signals.
Continue your research
What Balaji Amines Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Sudarshan Chemical Industries Ltd (Q1 FY27)
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
- Indo Borax & Ch. (Q1 FY27)
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
- SRF (Q1 FY27)
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…
- Deepak Fertilis. (Q1 FY27)
Long-term demand-supply balance looks stable with 6-7% market growth, supporting sustained revenues despite new capacity additions. Key concall takeaways from…